🎉 M&A multiples are live!
Check it out!

Amylyx Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Amylyx Pharmaceuticals and similar public comparables like Pharming, Julphar, and Galapagos.

Amylyx Pharmaceuticals Overview

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.


Founded

2014

HQ

United States of America
Employees

123

Website

amylyx.com

Financials

LTM Revenue $62.2M

LTM EBITDA n/a

EV

$171M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Amylyx Pharmaceuticals Financials

Amylyx Pharmaceuticals has a last 12-month revenue of $62.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Amylyx Pharmaceuticals achieved revenue of $87.4M and an EBITDA of -$291M.

Amylyx Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Amylyx Pharmaceuticals valuation multiples based on analyst estimates

Amylyx Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $381M $87.4M XXX XXX XXX
Gross Profit $19.2M $355M XXX XXX XXX
Gross Margin 5% 407% XXX XXX XXX
EBITDA $39.9M -$291M XXX XXX XXX
EBITDA Margin 10% -333% XXX XXX XXX
Net Profit -$198M $49.3M XXX XXX XXX
Net Margin -52% 56% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Amylyx Pharmaceuticals Stock Performance

As of April 15, 2025, Amylyx Pharmaceuticals's stock price is $4.

Amylyx Pharmaceuticals has current market cap of $346M, and EV of $171M.

See Amylyx Pharmaceuticals trading valuation data

Amylyx Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$171M $346M XXX XXX XXX XXX $-3.70

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Amylyx Pharmaceuticals Valuation Multiples

As of April 15, 2025, Amylyx Pharmaceuticals has market cap of $346M and EV of $171M.

Amylyx Pharmaceuticals's trades at 2.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Amylyx Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Amylyx Pharmaceuticals and 10K+ public comps

Amylyx Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $171M XXX XXX XXX
EV/Revenue 2.0x XXX XXX XXX
EV/EBITDA -0.6x XXX XXX XXX
P/E -1.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Amylyx Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Amylyx Pharmaceuticals Valuation Multiples

Amylyx Pharmaceuticals's NTM/LTM revenue growth is -100%

Amylyx Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $2.1M for the same period.

Over next 12 months, Amylyx Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Amylyx Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Amylyx Pharmaceuticals and other 10K+ public comps

Amylyx Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -77% XXX XXX XXX XXX
EBITDA Margin -333% XXX XXX XXX XXX
EBITDA Growth -829% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -433% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $2.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 161% XXX XXX XXX XXX
Opex to Revenue 291% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Amylyx Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Amylyx Pharmaceuticals M&A and Investment Activity

Amylyx Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Amylyx Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Amylyx Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Amylyx Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Amylyx Pharmaceuticals

When was Amylyx Pharmaceuticals founded? Amylyx Pharmaceuticals was founded in 2014.
Where is Amylyx Pharmaceuticals headquartered? Amylyx Pharmaceuticals is headquartered in United States of America.
How many employees does Amylyx Pharmaceuticals have? As of today, Amylyx Pharmaceuticals has 123 employees.
Who is the CEO of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals's CEO is Mr. Joshua Cohen.
Is Amylyx Pharmaceuticals publicy listed? Yes, Amylyx Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals trades under AMLX ticker.
When did Amylyx Pharmaceuticals go public? Amylyx Pharmaceuticals went public in 2022.
Who are competitors of Amylyx Pharmaceuticals? Similar companies to Amylyx Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals's current market cap is $346M
What is the current revenue of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals's last 12-month revenue is $62.2M.
What is the current EV/Revenue multiple of Amylyx Pharmaceuticals? Current revenue multiple of Amylyx Pharmaceuticals is 2.7x.
What is the current revenue growth of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals revenue growth between 2023 and 2024 was -77%.
Is Amylyx Pharmaceuticals profitable? Yes, Amylyx Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.